Peptilogics
What matters now
- $78Mannounced
Announced a $78M round on 16 Oct 2025.
A company that just raised has fresh capital, a new board and new vendors to choose.
FactPress release wires (PR Newswire, GlobeNewswire)For Investors, lenders, service providersFinancing history → - 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- unknown
- Rounds on record
- 1
- Disclosed raised
- $78.0Msum of rounds with a disclosed amount only
- Named investors
- 1
Financing history
- Oct 16, 2025Funding round · $78.0M (disclosed)Narya Capital Management, LLC (participant)Fact Press release · “Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial”
Investors on record
- Narya Capital Management, LLC round, participant Fact prnewswire.com
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.No firm portfolio page lists this company, so no outcome is stated.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
Timeline
- Oct 16, 2025Peptilogics announced Funding round of $78,000,000Round announced Fact Press release
Evidence
Every observation on this company
- Round announced: Funding round $78,000,000 Oct 16, 2025 Fact Press release
Record history
- Round announced2025-10-16source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.